The Food and Drug Administration on Tuesday approved Merck & Co.’s drug Keytruda for the treatment of blood cancer. The immunotherapy drug, first approved in 2014, can now be used to treat patients ...
Regulatory Recon: Merck's Keytruda Gets FDA Nod for Hodgkin Lymphoma FDA Panel Says Opana Risks Outweigh Benefits (15 March 2017) Welcome to Regulatory Reconnaissance, your daily regulatory news and ...
Dec 6 (Reuters) - Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results